Research Article
Human Platelets Take up Anti-VEGF Agents
Figure 5
Silver enhancement (preembedding) using immunoelectron microscopy in human platelets exposed to pharmacologic inhibitors: staurosporine and cytochalasin D. Gold particle (1 nm)-labeled anti-VEGF agents: (a) ranibizumab, (b) aflibercept, and (c) bevacizumab. (a, b, c) Platelets without exposure to pharmacologic inhibitors. (d, e, f) Platelets exposed to staurosporine. (g, h, i) Platelets exposed to cytochalasin D. Scale bar represents 1 µm.
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |
(g) |
(h) |
(i) |